This information is intended for health professionals. Further details are in Pharmacist administration of drugs and vaccines — Section 8.10, PharmaCare Policy Manual
On this page: Fee and procedures | Non-pharmacist administrations | How to claim | Flu vaccines (2023-2024) | COVID-19 vaccines | Publicly funded vaccine PINs | Resources
PharmaCare pays a fee when an authorized pharmacist, and in some cases non-pharmacist, administers a publicly funded vaccine.
Key details:
Refer to the BCCDC’s B.C. Immunization Manual for criteria, immunization schedule and other important information.
Pharmacies can claim the administration fee when an authorized regulated professional administers an influenza or COVID-19 vaccine (e.g., pharmacist, registered nurse).
Pharmacies can also claim the fee when administered by the following health professionals in a B.C. pharmacy, when supervised by a regulated professional:
As authorized under the November 4, 2022 PHO, these un-regulated professionals must have completed the required education to administer vaccines, and must be supervised by an authorized regulated professional.
Refer to COVID-19 claims and flu vaccine claims for procedures for those vaccines.
If administered to eligible patients for publicly funded vaccines:
Patients who are not eligible:
During the annual campaign, pharmacies may submit claims for flu vaccinations.
The publicly funded flu vaccines for the 2023 – 2024 season are:
Private supply vaccinations are eligible for PharmaCare’s drug administration fee of $11.41.
Three publicly funded flu vaccines are also available for private supply.
If product is both private and public supply:
If product is uniquely private:
You must note that a vaccination is for an LTC or AL resident. In the Immunization Information section, select "AL resident" or "LTC resident" from the Reason for Immunization dropdown menu.
If your pharmacy has not pre-registered residents for appointments, record the vaccination as a walk-in. Open the resident's profile, and click the "Check-In" button.
Vaccine product group | Vaccine product | PIN |
---|---|---|
Haemophilus b conjugate | Act-HIB® | 66128205 |
Haemophilus influenzae type b conjugate | Hiberix® | 66128170 |
Hepatitis A | Avaxim™ | 66124760 |
Avaxim™ Pediatric | 66124831 | |
Havrix® 1440 | 66124768 | |
Havrix® Junior 720 | 66124769 | |
Vaqta® Adult | 66124794 | |
Vaqta® Pediatric | 66124795 | |
Hepatitis B | Engerix® B | 66124764 |
Engerix® B Pediatric | 66128130 | |
Recombivax HB® | 66124789 | |
Recombivax HB® Adult Dialysis | 66124790 | |
Recombivax HB® Pediatric | 66124791 | |
Human papillomavirus (2 strains) | Cervarix™ | 66127902 |
Human papillomavirus (9 strains) | Gardasil® 9 | 66128117 |
Measles, mumps, rubella | MMR-II™ | 66124781 |
Priorix™ | 66124834 | |
Measles, mumps, rubella, and varicella virus | Proquad® | 66128068 |
Priorix-Tetra | 66128069 | |
Meningococcal group B | Bexsero | 66128075 |
Meningococcal C conjugate | Meningitec™ | 66124832 |
Menjugate® | 66128114 | |
Neis Vac-C® | 66124782 | |
Pneumococcal conjugate 13-valent | Prevnar 13 | 66128070 |
Pneumococcal 23-valent | Pneumovax® 23 | 66124785 |
IPV (polio for travel indications) | Imovax® Polio | 66124773 |
Quadrivalent meningococcal conjugate | Menveo | 66128071 |
Menactra | 66128072 | |
Nimenrix® | 66128152 | |
Rabies | RabAvert® | 66124788 |
Smallpox and monkeypox | Imvamune® | 66128369 |
Tetanus, diphtheria | Td Adsorbed | 66124793 |
Tetanus, diphtheria, acellular pertussis | Adacel® | 66124758 |
Boostrix® | 66127901 | |
Tetanus, diphtheria, acellular pertussis, polio adsorbed | Quadracel® | 66124787 |
Adacel® Polio | 66128131 | |
Boostrix®-Polio | 66128094 | |
Tetanus, diphtheria, acellular pertussis, polio, hepatitis B, haemophilus influenzae type b adsorbed | Infanrix hexa® | 66124776 |
Tetanus, diphtheria, IPV (polio for travel indications) | Td Polio Adsorbed | 66124792 |
Varicella | Varilrix® | 66124796 |
Varivax® III | 66124797 |
For vaccine availability, consult your local health unit or health authority.